Efficacy of Teicoplanin Monotherapy Following Initial Standard Therapy in Enterococcus Faecalis Infective Endocarditis: a Retrospective Cohort Study

Overview

Journal Infection

Date 2019 Feb 28

PMID 30809761

Citations 5

Authors

Thomas De Nadai

Mathilde Francois

Agnes Sommet

Damien Dubois

David Metsu

Marion Grare

Bruno Marchou

Pierre Delobel

Guillaume Martin-Blondel

Affiliations

Soon will be listed here.

Abstract

Purpose: Teicoplanin is often used in Enterococcus faecalis infective endocarditis as a relay in case of penicillin side effects, or in outpatients. We assessed the efficacy of teicoplanin used as continuation therapy after initial standard treatment of E. faecalis endocarditis.

Methods: All adult patients consecutively diagnosed between 1997 and 2016 for E. faecalis endocarditis were retrospectively reviewed. Patients who received standard therapy (ST) were compared to those switched to teicoplanin to complete the treatment (teicoplanin therapy, TT).

Results: Seventy-one patients were enrolled: 34 in the ST group and 37 in the TT group. Amoxicillin was replaced by teicoplanin after a median duration of 18 days (IQ 12-21). Teicoplanin (5.8 ± 2.3 mg/kg) was administered for a median duration of 29 days (IQ 25-34). Gentamicin therapy was similar. Overall duration of antimicrobial therapy was 42 days (IQ 35-43) in the ST group, and 46 days (IQ 43-49) in the TT group (p = 0.001). Global and endocarditis-related mortality rates were 22/34 (65%) and 13/34 (38%) in the ST group, and 14/37 (38%) and 3/37 (8%) in the TT group (p ≤ 0.05). Relapses occurred in 2/26 patients who survived the treatment phase in the ST group (8%) and in 3/37 in the TT group (8%, p = 0.68). All relapses in the TT group occurred in patients presenting prosthetic valve endocarditis. Finally, 20 patients were cured in the ST group (59%), and 33 patients in the TT group (89%, p = 0.003).

Conclusions: In E. faecalis endocarditis, the switch to teicoplanin in selected patients following an initial phase of standard treatment represents an alternative, particularly for outpatient therapy. Caution should be exercised in cases of prosthetic valve endocarditis.

Citing Articles

Combination therapy versus monotherapy: retrospective analysis of antibiotic treatment of enterococcal endocarditis.

Saman R, Primus C, West R, Woldman S, Sandoe J BMC Infect Dis. 2025; 25(1):92.

PMID: 39833745 PMC: 11748874. DOI: 10.1186/s12879-025-10451-2.

C-terminal deletion of RelA protein is suggested as a possible cause of infective endocarditis recurrence with .

Ortiz de la Rosa J, Martin-Gutierrez G, Casimiro-Soriguer C, Gimeno-Gascon M, Cisneros J, de Alarcon A Antimicrob Agents Chemother. 2024; 68(3):e0108323.

PMID: 38349158 PMC: 10923276. DOI: 10.1128/aac.01083-23.

Treatment of Infective Endocarditis: A Continuing Challenge.

Herrera-Hidalgo L, Fernandez-Rubio B, Luque-Marquez R, Lopez-Cortes L, Gil-Navarro M, de Alarcon A Antibiotics (Basel). 2023; 12(4).

PMID: 37107066 PMC: 10135260. DOI: 10.3390/antibiotics12040704.

Native and Prosthetic Simultaneously Double Valve Infective Endocarditis with -Case-Based Review.

Haliga R, Sorodoc V, Morarasu B, Coman A, Ceasovschih A, Sirbu O J Pers Med. 2023; 13(2).

PMID: 36836534 PMC: 9964386. DOI: 10.3390/jpm13020300.

Ampicillin Plus Ceftriaxone Combined Therapy for Infective Endocarditis in OPAT.

Herrera-Hidalgo L, Lomas-Cabezas J, Lopez-Cortes L, Luque-Marquez R, Lopez-Cortes L, Martinez-Marcos F J Clin Med. 2022; 11(1).

PMID: 35011748 PMC: 8745305. DOI: 10.3390/jcm11010007.

References

Lopez P, Gavalda J, Martin M, Almirante B, Gomis X, Azuaje C . Efficacy of teicoplanin-gentamicin given once a day on the basis of pharmacokinetics in humans for treatment of enterococcal experimental endocarditis. Antimicrob Agents Chemother. 2001; 45(5):1387-93. PMC: 90478. DOI: 10.1128/AAC.45.5.1387-1393.2001. View

Nallapareddy S, Duh R, Singh K, Murray B . Molecular typing of selected Enterococcus faecalis isolates: pilot study using multilocus sequence typing and pulsed-field gel electrophoresis. J Clin Microbiol. 2002; 40(3):868-76. PMC: 120268. DOI: 10.1128/JCM.40.3.868-876.2002. View

Eliopoulos G, Moellering Jr R . Contribution of animal models in the search for effective therapy for endocarditis due to enterococci with high-level resistance to gentamicin. Clin Infect Dis. 1992; 15(1):58-62. DOI: 10.1093/clinids/15.1.58. View

Pavleas J, Skiada A, Daikos G, Pefanis A, Giamarellos-Bourboulis E, Kanellakopoulou K . Efficacy of teicoplanin, administered in two different regimens, in the treatment of experimental endocarditis due to Enterococcus faecalis. J Chemother. 2008; 20(2):208-12. DOI: 10.1179/joc.2008.20.2.208. View

Tacconelli E, Smith G, Hieke K, Lafuma A, Bastide P . Epidemiology, medical outcomes and costs of catheter-related bloodstream infections in intensive care units of four European countries: literature- and registry-based estimates. J Hosp Infect. 2009; 72(2):97-103. DOI: 10.1016/j.jhin.2008.12.012. View

Svetitsky S, Leibovici L, Paul M . Comparative efficacy and safety of vancomycin versus teicoplanin: systematic review and meta-analysis. Antimicrob Agents Chemother. 2009; 53(10):4069-79. PMC: 2764163. DOI: 10.1128/AAC.00341-09. View

Yao J, Eliopoulos G, Moellering Jr R . Efficacy of teicoplanin in two dosage regimens for experimental endocarditis caused by a beta-lactamase-producing strain of Enterococcus faecalis with high-level resistance to gentamicin. Antimicrob Agents Chemother. 1990; 34(5):827-30. PMC: 171700. DOI: 10.1128/AAC.34.5.827. View

Chirouze C, Athan E, Alla F, Chu V, Corey G, Selton-Suty C . Enterococcal endocarditis in the beginning of the 21st century: analysis from the International Collaboration on Endocarditis-Prospective Cohort Study. Clin Microbiol Infect. 2013; 19(12):1140-7. DOI: 10.1111/1469-0691.12166. View

Hoen B, Duval X . Clinical practice. Infective endocarditis. N Engl J Med. 2013; 368(15):1425-33. DOI: 10.1056/NEJMcp1206782. View

10.

Cremieux A, Maziere B, Vallois J, Ottaviani M, Azancot A, Raffoul H . Evaluation of antibiotic diffusion into cardiac vegetations by quantitative autoradiography. J Infect Dis. 1989; 159(5):938-44. DOI: 10.1093/infdis/159.5.938. View

11.

Leport C, Perronne C, Massip P, Canton P, Leclercq P, Bernard E . Evaluation of teicoplanin for treatment of endocarditis caused by gram-positive cocci in 20 patients. Antimicrob Agents Chemother. 1989; 33(6):871-6. PMC: 284248. DOI: 10.1128/AAC.33.6.871. View

12.

Martino P, Venditti M, Micozzi A, Brandimarte C, Gentile G, Santini C . Teicoplanin in the treatment of gram-positive-bacterial endocarditis. Antimicrob Agents Chemother. 1989; 33(8):1329-34. PMC: 172649. DOI: 10.1128/AAC.33.8.1329. View

13.

Moulis G, Lapeyre-Mestre M, Palmaro A, Pugnet G, Montastruc J, Sailler L . French health insurance databases: What interest for medical research?. Rev Med Interne. 2014; 36(6):411-7. DOI: 10.1016/j.revmed.2014.11.009. View

14.

Habib G, Lancellotti P, Antunes M, Bongiorni M, Casalta J, Del Zotti F . 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the.... Eur Heart J. 2015; 36(44):3075-3128. DOI: 10.1093/eurheartj/ehv319. View

15.

Baddour L, Wilson W, Bayer A, Fowler Jr V, Tleyjeh I, Rybak M . Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Scientific Statement for Healthcare Professionals From the American Heart Association. Circulation. 2015; 132(15):1435-86. DOI: 10.1161/CIR.0000000000000296. View

16.

Peeters O, Ferry T, Ader F, Boibieux A, Braun E, Bouaziz A . Teicoplanin-based antimicrobial therapy in Staphylococcus aureus bone and joint infection: tolerance, efficacy and experience with subcutaneous administration. BMC Infect Dis. 2016; 16(1):622. PMC: 5093939. DOI: 10.1186/s12879-016-1955-7. View

17.

Gil-Navarro M, Lopez-Cortes L, Luque-Marquez R, Galvez-Acebal J, de Alarcon-Gonzalez A . Outpatient parenteral antimicrobial therapy in Enterococcus faecalis infective endocarditis. J Clin Pharm Ther. 2017; 43(2):220-223. DOI: 10.1111/jcpt.12635. View

18.

Cazaubon Y, Venisse N, Mimoz O, Maire P, Ducher M, Bourguignon L . Population pharmacokinetics of teicoplanin administered by subcutaneous or intravenous route and simulation of optimal loading dose regimen. J Antimicrob Chemother. 2017; 72(10):2804-2812. DOI: 10.1093/jac/dkx242. View

19.

Glupczynski Y, Lagast H, Van der Auwera P, Thys J, Crokaert F, Yourassowsky E . Clinical evaluation of teicoplanin for therapy of severe infections caused by gram-positive bacteria. Antimicrob Agents Chemother. 1986; 29(1):52-7. PMC: 180363. DOI: 10.1128/AAC.29.1.52. View

20.

Iversen K, Ihlemann N, Gill S, Madsen T, Elming H, Jensen K . Partial Oral versus Intravenous Antibiotic Treatment of Endocarditis. N Engl J Med. 2018; 380(5):415-424. DOI: 10.1056/NEJMoa1808312. View